<DOC>
	<DOCNO>NCT02124850</DOCNO>
	<brief_summary>Protocol VRXP-A106 enroll patient Stage II-IVA head neck cancer patient treat surgical resection . Cetuximab motolimod ( Cohort 1 ) ; cetuximab , motolimod , nivolumab ( Cohort 2 ) administer 3-4 week period surgery . The primary objective study determine extent administration neoadjuvant motolimod plus cetuximab motolimod plus cetuximab nivolumab modulates immune biomarkers ( NK , mDC T cell activation well tumor infiltration serum cytokine ) peripheral blood head neck cancer tumor . An exploratory objective study ass whether modulation biomarkers describe predict anti-tumor response .</brief_summary>
	<brief_title>A Phase Ib Study Neoadjuvant Cetuximab Plus Motolimod Cetuximab Plus Motolimod Plus Nivolumab</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Previously untreated stage II , III , IVA histologically cytologically confirm squamous cell carcinoma head neck Primary tumor oral cavity , oropharynx , hypopharynx , larynx Macroscopic complete resection primary tumor must plan Age â‰¥ 18 year ECOG performance status 01 Adequate hematologic , renal hepatic function Have sign write informed consent Subjects fail meet inclusion criterion Primary tumor sinus , paranasal sinus , nasopharynx , unknown primary tumor Prior severe infusion reaction monoclonal antibody Pregnancy breastfeed Evidence distant metastasis Any malignancy active within 5 year except nonmelanoma skin cancer carcinoma situ cervix , DCIS LCIS breast Prior history head neck cancer Prior therapy motolimod , nivolumab , agent target PD1/PDL1 Prior therapy target EGFR pathway Acute hepatitis , know HIV , active uncontrolled infection Patients active autoimmune disease History uncontrolled cardiac disease within prior 6 month Uncontrolled peptic gastric ulcer disease , gastrointestinal bleeding within prior 6 month Active alcohol abuse illness circumstance carry likelihood inability comply study treatment followup otherwise compromise study 's objective Treatment nonapproved investigational drug within 30 day prior Day 1 study treatment Live vaccine within 30 day plan start study therapy History pneumonitis interstitial lung disease History allergic reaction attribute compound similar chemical biologic composition nivolumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>